NASDAQ:BCLI - Brainstorm Cell Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.93 -0.05 (-1.26 %)
(As of 09/21/2018 04:00 PM ET)
Previous Close$3.98
Today's Range$3.91 - $3.98
52-Week Range$2.88 - $5.35
Volume34,200 shs
Average Volume91,136 shs
Market Capitalization$81.85 million
P/E Ratio-15.12
Dividend YieldN/A
Beta2.01
Brainstorm Cell Therapeutics logoBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Receive BCLI News and Ratings via Email

Sign-up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BCLI
CUSIPN/A
Phone201-488-0460

Debt

Debt-to-Equity RatioN/A
Current Ratio2.40
Quick Ratio2.40

Price-To-Earnings

Trailing P/E Ratio-15.12
Forward P/E Ratio-8.02
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.31 per share
Price / Book12.68

Profitability

EPS (Most Recent Fiscal Year)($0.26)
Net Income$-4,950,000.00
Net MarginsN/A
Return on Equity-108.26%
Return on Assets-56.53%

Miscellaneous

Employees24
Outstanding Shares20,670,000
Market Cap$81.85 million

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Frequently Asked Questions

What is Brainstorm Cell Therapeutics' stock symbol?

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) announced its quarterly earnings data on Monday, July, 23rd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.02. View Brainstorm Cell Therapeutics' Earnings History.

When is Brainstorm Cell Therapeutics' next earnings date?

Brainstorm Cell Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, October, 16th 2018. View Earnings Estimates for Brainstorm Cell Therapeutics.

What price target have analysts set for BCLI?

2 Wall Street analysts have issued 12-month price targets for Brainstorm Cell Therapeutics' shares. Their predictions range from $9.00 to $11.00. On average, they expect Brainstorm Cell Therapeutics' share price to reach $10.00 in the next year. This suggests a possible upside of 154.5% from the stock's current price. View Analyst Price Targets for Brainstorm Cell Therapeutics.

What is the consensus analysts' recommendation for Brainstorm Cell Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Brainstorm Cell Therapeutics.

What are Wall Street analysts saying about Brainstorm Cell Therapeutics stock?

Here are some recent quotes from research analysts about Brainstorm Cell Therapeutics stock:
  • 1. Maxim Group analysts commented, "BrainStorm announced that the Office (USPTO) granted a new US patent titled Methods of Neurotrophic Factors". The allowed claims for the patent cover the method for generating NurOwn (MSC-NTF cells) in industrial amounts for clinical practice." (9/13/2018)
  • 2. HC Wainwright analysts commented, "We note that Right to Try" laws exist in 38 states, today: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Washington and Wyoming — but this federal bill would introduce legislation across state lines." (5/29/2018)

Who are some of Brainstorm Cell Therapeutics' key competitors?

Who are Brainstorm Cell Therapeutics' key executives?

Brainstorm Cell Therapeutics' management team includes the folowing people:
  • Mr. Chaim Lebovits, Pres & CEO (Age 47)
  • Dr. Ralph Z. Kern, COO & Chief Medical Officer (Age 60)
  • Mr. Uri Yablonka, Exec. VP, Chief Bus. Officer & Director (Age 41)
  • Mr. Eyal Rubin, CFO & Treasurer (Age 42)
  • Dr. Yael Gothelf Ph.D., VP of Scientific and Regulatory Affairs

Has Brainstorm Cell Therapeutics been receiving favorable news coverage?

Press coverage about BCLI stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Brainstorm Cell Therapeutics earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Brainstorm Cell Therapeutics.

Who are Brainstorm Cell Therapeutics' major shareholders?

Brainstorm Cell Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.56%). Company insiders that own Brainstorm Cell Therapeutics stock include Irit Arbel, June Sherie Almenoff, Ralph Dr Kern and Uri Yablonka. View Institutional Ownership Trends for Brainstorm Cell Therapeutics.

Which major investors are buying Brainstorm Cell Therapeutics stock?

BCLI stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include Irit Arbel, June Sherie Almenoff, Ralph Dr Kern and Uri Yablonka. View Insider Buying and Selling for Brainstorm Cell Therapeutics.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Brainstorm Cell Therapeutics' stock price today?

One share of BCLI stock can currently be purchased for approximately $3.93.

How big of a company is Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics has a market capitalization of $81.85 million. The biotechnology company earns $-4,950,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. Brainstorm Cell Therapeutics employs 24 workers across the globe.

How can I contact Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]


MarketBeat Community Rating for Brainstorm Cell Therapeutics (NASDAQ BCLI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  282
MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. Vote "Outperform" if you believe BCLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel